Paper119786
Description and classification of the newer cephalosporins and their relationships with the established compounds.
O'Callaghan CH. J Antimicrob Chemother, 1979. Cited by 100 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Description and classification of the newer cephalosporins and their relationships with the established compounds. Papers, record 119786. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/119786
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Description and classification of the newer cephalosporins and their relationships with the established compounds.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cephalosporins | Major topic |
| Administration, Oral | |
| Animal Diseases | |
| Animals | |
| Cephalosporinase | |
| Drug Resistance, Microbial | |
| Humans | |
| Infusions, Parenteral | |
| Injections, Intramuscular | |
| Intestinal Absorption | |
| Kinetics | |
| Pseudomonas aeruginosa |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35,658,710 | Liverpool Epidemic Strain Isolates of Pseudomonas aeruginosa Display High Levels of Antimicrobial Resistance during Both Planktonic and Biofilm Growth. | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/35658710 | PubMed |
| 29,769,008 | Biochemical and Haematological Predictors of Reduced Neutrophil Granulocyte Count associated with Intravenous Ceftriaxone Treatment. | Rev Recent Clin Trials | 2018 | https://conductscience.org/library/papers/29769008 | PubMed |
| 8,665,470 | beta-Lactamases in laboratory and clinical resistance. | Clin Microbiol Rev | 1995 | https://conductscience.org/library/papers/8665470 | PubMed |
| 7,247,358 | In vitro susceptibility of Mycobacterium fortuitum to cefoxitin. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/7247358 | PubMed |
| 7,035,856 | Antibiotic resistance in pathogenic and producing bacteria, with special reference to beta-lactam antibiotics. | Microbiol Rev | 1981 | https://conductscience.org/library/papers/7035856 | PubMed |
| 6,974,539 | BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6974539 | PubMed |
| 6,972,734 | beta-Lactamases and resistance to cephalosporins. | Antonie Van Leeuwenhoek | 1981 | https://conductscience.org/library/papers/6972734 | PubMed |
| 6,972,194 | Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies. | Antimicrob Agents Chemother | 1980 | https://conductscience.org/library/papers/6972194 | PubMed |
| 6,961,887 | In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6961887 | PubMed |
| 6,919,412 | Comparative in vitro study of temocillin (BRL 17421), a new penicillin. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6919412 | PubMed |
| 6,800,462 | Twenty-one years of beating beta-lactamases. | Br Med J (Clin Res Ed) | 1982 | https://conductscience.org/library/papers/6800462 | PubMed |
| 6,742,815 | Antimicrobial activity of SK&F 88070, an expanded-spectrum cephalosporin with high and prolonged levels in blood. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6742815 | PubMed |
| 6,604,496 | In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6604496 | PubMed |
| 6,601,063 | The current state of cephalosporin antibiotics: microbiological aspects. | Infection | 1983 | https://conductscience.org/library/papers/6601063 | PubMed |
| 6,455,966 | Pharmacokinetics of cefoperazone in patients with neoplastic disease. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6455966 | PubMed |
| 6,335,134 | Selection of resistant mutants of Citrobacter freundii by second and third-generation cephalosporins and imipenem. | Infection | 1984 | https://conductscience.org/library/papers/6335134 | PubMed |
| 6,279,094 | Interaction between non-classical beta-lactam compounds and the Zn2+-containing G and serine R61 and R39 D-alanyl-D-alanine peptidases. | Biochem J | 1981 | https://conductscience.org/library/papers/6279094 | PubMed |
| 6,276,458 | Cefotaxime in treatment of meningitis and ventriculitis? Evaluation of drug concentrations in human cerebrospinal fluid. | Intensive Care Med | 1982 | https://conductscience.org/library/papers/6276458 | PubMed |
| 6,275,779 | Pharmacokinetics of ceftriaxone in humans. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6275779 | PubMed |
| 6,100,422 | Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6100422 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/119786
GET https://conductscience.org/api/papers/v1/119786/cited_by?page=2